Clinical Trial Update: The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating suvorexant for sleep, stress, and cue-reactivity in methamphetamine use disorder was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methamphetamine Use Disorder

Drugs mentioned

• Belsomra (suvorexant)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Methamphetamine Use Disorder | Phase 2 | Status: TERMINATED | Results posted: 2025-04-29